Triple

T1613291
Position Surface form Disambiguated ID Type / Status
Subject Public Health Service Act E34657 entity
Predicate authorizes P273 FINISHED
Object 340B Drug Pricing Program E163275 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: 340B Drug Pricing Program | Statement: [Public Health Service Act, authorizes, 340B Drug Pricing Program]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: 340B Drug Pricing Program
Context triple: [Public Health Service Act, authorizes, 340B Drug Pricing Program]
  • A. 340B Drug Pricing Program chosen
    The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
  • B. Prescription Drug User Fee Act of 1992
    The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
  • C. Prescription Drug Take Back Program
    The Prescription Drug Take Back Program is a U.S. Drug Enforcement Administration initiative that provides safe, convenient, and responsible ways for the public to dispose of unused or expired prescription medications.
  • D. Drug Price Competition and Patent Term Restoration Act of 1984
    The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
  • E. Center for Medicare and Medicaid Innovation
    The Center for Medicare and Medicaid Innovation is a federal agency within CMS that tests and implements new payment and service delivery models to improve quality and reduce costs in Medicare, Medicaid, and CHIP.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a885ffc5ec819091afa325d5f9611c completed March 4, 2026, 7:20 p.m.
NER Named-entity recognition batch_69a9098e245c8190b0169b648434aa49 completed March 5, 2026, 4:41 a.m.
NED1 Entity disambiguation (via context triple) batch_69ad51c751308190a89f6462ee365418 completed March 8, 2026, 10:39 a.m.
Created at: March 4, 2026, 7:28 p.m.